PulSar is a new study developed for people affected by sarcoidosis, a disease that affects multiple organs in the body, but most prevalently the lungs.

In a given year, approximately 185,000 patients with sarcoidosis seek medical care in the U.S.1

 

In one study of 500 patients, 43% were being treated for persistent disease by 5 years after diagnosis.2

PulSar is a Phase 4 multicenter, randomized, double blind, placebo controlled pilot study to assess the efficacy and safety of Acthar® Gel in subjects with Pulmonary Sarcoidosis.

Study Duration

The study is designed to last for 24 weeks, with an optional open-label, 24 week extension period.

Screening period

Treatment

Open-label treatment

Follow-up visit*

*Follow-up visit occurs 28 days after last dose of study drug

To qualify for the study,
participants must:*

Be between 18 and 90 years of age

Have biopsy-confirmed sarcoidosis for >1 year prior to initial visit

Be on a stable prednisone dose for at least 4 weeks prior to initial visit

*Other criteria are necessary to qualify for this study. Talk to your doctor about all qualifications.

Interested in enrolling?

Find a Trial Site